What do systematic reviews say?

441 questions · 453 findings · 35 reviews · HIV/AIDS · Headline outcomes only

Sort:Best matchNewestHighest certainty Download CSV

No studies found 18 · 4%GRADE not reported 9 · 2%Very low 126 · 27.8%Low 127 · 28%Moderate 152 · 33.6%High 21 · 4.6%

Adjunctive corticosteroids vs no such treatment

Death at 1 month (adults) · patients with Pneumocystis jiroveci pneumonia and HIV infection

Adjunctive corticosteroids leads to lower death at 1 month (adults) compared with no such treatment (high certainty).

1 finding from 1 review

Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection 2015 · Cochrane Headline outcomes only
RR 0.56 [0.32, 0.98]
6 studies · 489 participants
High

Adjunctive corticosteroids vs no such treatment

Death at 3 to 4 months (adults) · patients with Pneumocystis jiroveci pneumonia and HIV infection

Adjunctive corticosteroids leads to lower death at 3 to 4 months (adults) compared with no such treatment (high certainty).

1 finding from 1 review

Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection 2015 · Cochrane Headline outcomes only
RR 0.59 [0.41, 0.85]
5 studies · 448 participants
High

Adjunctive corticosteroids vs no such treatment

Death in hospital; children · patients with Pneumocystis jiroveci pneumonia and HIV infection

Adjunctive corticosteroids showed no clear difference in death in hospital; children compared with no such treatment (moderate certainty).

1 finding from 1 review

Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection 2015 · Cochrane Headline outcomes only
RR 0.81 [0.51, 1.29]
1 study · 100 participants
Moderate

Adjunctive corticosteroids vs no such treatment

Need for mechanical ventilation · patients with Pneumocystis jiroveci pneumonia and HIV infection

Adjunctive corticosteroids probably leads to lower need for mechanical ventilation at 1 month compared with no such treatment (moderate certainty).

1 finding from 1 review

Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection 2015 · Cochrane Headline outcomes only
RR 0.38 [0.2, 0.73]
3 studies · 388 participants
Moderate

HAART + ABV vs HAART alone

All‐cause mortality · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + ABV showed no clear difference in mortality compared with HAART alone (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 0.92 [0.45, 1.88]
1 study · 100 participants
Moderate

HAART + liposomal anthracycline vs HAART alone

Kaposi's sarcoma IRIS · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + liposomal anthracycline showed no clear difference in kaposi's sarcoma IRIS compared with HAART alone (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 0.49 [0.16, 1.55]
1 study · 129 participants
Moderate

HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin

Progression of Kaposi's sarcoma · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + paclitaxel showed no clear difference in progression of Kaposi's sarcoma compared with HAART + pegylated liposomal doxorubicin (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 1.04 [0.07, 15.73]
1 study · 49 participants
Moderate

HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin

Clinical response ‐ complete response · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + paclitaxel showed no clear difference in clinical response ‐ complete response compared with HAART + pegylated liposomal doxorubicin (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 2.08 [0.2, 21.5]
1 study · 49 participants
Moderate

HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin

Primary outcome: partial clinical response · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + paclitaxel showed no clear difference in clinical response ‐ partial response compared with HAART + pegylated liposomal doxorubicin (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 1.04 [0.5, 2.17]
1 study · 49 participants
Moderate

HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin

Clinical response ‐ stable disease · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + paclitaxel showed no clear difference in clinical response ‐ stable disease compared with HAART + pegylated liposomal doxorubicin (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 0.63 [0.27, 1.45]
1 study · 49 participants
Moderate

HAART + pegylated liposomal doxorubicin vs HAART + liposomal daunorubicin

Progression of Kaposi's sarcoma · HIV‐infected adults with severe (T1) Kaposi's sarcoma

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 46 participants
Moderate

Liposomal daunorubicin vs ABV

Progression of Kaposi's sarcoma · HIV‐infected adults with severe (T1) Kaposi's sarcoma

Liposomal daunorubicin showed no clear difference in progression of Kaposi's sarcoma compared with ABV (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 0.78 [0.34, 1.82]
1 study · 227 participants
Moderate

Liposomal daunorubicin vs ABV

Clinical response ‐ complete response · HIV‐infected adults with severe (T1) Kaposi's sarcoma

Liposomal daunorubicin showed no clear difference in clinical response ‐ complete response compared with ABV (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 2.87 [0.3, 27.19]
1 study · 227 participants
Moderate

Liposomal daunorubicin vs ABV

Primary outcome: partial clinical response · HIV‐infected adults with severe (T1) Kaposi's sarcoma

Liposomal daunorubicin showed no clear difference in clinical response ‐ partial response compared with ABV (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 0.83 [0.53, 1.31]
1 study · 227 participants
Moderate

Liposomal daunorubicin vs ABV

Clinical response ‐ overall response · HIV‐infected adults with severe (T1) Kaposi's sarcoma

Liposomal daunorubicin showed no clear difference in clinical response ‐ overall response compared with ABV (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 0.9 [0.58, 1.38]
1 study · 227 participants
Moderate

HAART + ABV vs HAART alone

Progressive disease · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + ABV probably leads to lower progressive disease compared with HAART alone (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 0.1 [0.01, 0.75]
1 study · 100 participants
Moderate

Liposomal daunorubicin vs ABV

Clinical response ‐ stable disease · HIV‐infected adults with severe (T1) Kaposi's sarcoma

Liposomal daunorubicin showed no clear difference in clinical response ‐ stable disease compared with ABV (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 1.08 [0.87, 1.33]
1 study · 227 participants
Moderate

Liposomal daunorubicin vs ABV

Adverse events · HIV‐infected adults with severe (T1) Kaposi's sarcoma

Liposomal daunorubicin showed no clear difference in adverse events compared with ABV (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 1.01 [0.96, 1.06]
1 study · 227 participants
Moderate

Oral etoposide vs ABV

All‐cause mortality · HIV‐infected adults with severe (T1) Kaposi's sarcoma

Oral etoposide showed no clear difference in mortality compared with ABV (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 1.08 [0.98, 1.19]
1 study · 178 participants
Moderate

Bleomycin vs ABV

All‐cause mortality · HIV‐infected adults with severe (T1) Kaposi's sarcoma

It is very uncertain whether bleomycin changes mortality compared with ABV (very low certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 1.09 [0.87, 1.36]
1 study · 24 participants
Very low